What is LOPJLB’s current signal on QURE?

LOPJLB’s latest quantitative signal on uniQure N.V. (QURE) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is QURE in?

uniQure N.V. (QURE) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does uniQure N.V. (QURE) do?

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntingtonâs disease…

uniQure N.V. (QURE)

COMPARE

Healthcare · Biotechnology · NASDAQ · NL

$21.28-2.56%Close

SELLCRISIS · day 14

[SCORES & PROFILE]

FUND: 0
VALUE: 0
GROWTH: 2
GARP: 2
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-67.2%

REV YoY-

ROE-112.0%

EPS YoY-

ROA-25.6%

GROSS

-1089

NET

-1351

[VALUATION]

P/E TTM-5.27

P/E FWD-

SECTOR PE20.34

INDUSTRY PE13.84

P/B4.35

P/FCF-

EV/EBITDA-6.22

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E19.39

ALTMAN Z-

CURR RATIO10.01

ND/EBITDA-

BETA0.94

FAQ

What is LOPJLB’s current signal on QURE?: LOPJLB’s latest quantitative signal on uniQure N.V. (QURE) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is QURE in?: uniQure N.V. (QURE) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does uniQure N.V. (QURE) do?: uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntingtonâs disease…

uniQure N.V. (QURE)

Key stats

Industry peers

Prediction markets

FUNDAMENTALS

Company news

FAQ